Tenaya Therapeutics, Inc. entered a research collaboration agreement with Alnylam Pharmaceuticals to discover novel human genetic targets for the potential development of disease-modifying treatments for cardiovascular diseases. Under the terms of the agreement, Tenaya Therapeutics will validate up to 15 gene targets. Tenaya will receive up to USD 10 million in the form of an upfront payment, in addition to reimbursement for related costs incurred over the two-year validation term.
Alnylam will be responsible for all development and commercialization activities of therapeutics associated with the identified gene targets. Tenaya may be eligible to receive as much as USD 1,130 million in development and commercial milestone payments from Alnylam should all novel genetic targets lead to approved therapeutics for cardiovascular disease. Under the terms of the agreement, Tenaya Therapeutics will validate up to 15 gene targets.
Tenaya will receive up to $10 million in the form of an upfront payment, in addition to reimbursement for related costs incurred over the two-year validation term. Alnylam will be responsible for all development and commercialization activities of therapeutics associated with the identified gene targets. Tenaya may be eligible to receive as much as $1.13 billion in development and commercial milestone payments from Alnylam should all novel genetic targets lead to approved therapeutics for cardiovascular disease.
